CIOREVIEW >> OpenSource >>

AiCure Announces the Launch of OpenDBM

By CIOReview | Tuesday, November 10, 2020

AiCure releases OpenDBM, an open-source version of its computer vision and AI-powered digital biomarker platform for clinical trials.

FREMONT, CA: AiCure, an AI and advanced data analytics company missioned on improving clinical trials, introduces OpenDBM, an open-source type of its computer vision and AI-powered digital biomarker platform, at CNS Summit 2020. The platform’s transparent framework will offer the scientific community access to AiCure’s digital biomarker algorithms and the potential to apply them to their own datasets to quantify patient responses to treatment, such as facial, vocal, and motor characteristics. By breaking down challenges to proprietary technology, AiCure visions to encourage scientific scrutiny and partnership to not only advance the development of digital biomarkers for remote assessment but also enhance the understanding of illness and patient behavior.

Scientifically proven digital biomarkers hold significant promise to better a clinical trial’s objectivity, sensitivity, and frequency of evaluation. Despite this ability, this means of measuring patient behavior is shrouded in mystery, as proprietary machine learning models are not accessible to scientists to assess independently. At CNS Summit 2020, AiCure will come to Merck and Kent State University to discuss the industry demand to democratize access to these algorithms to improve their validity and deepen the pool of clinical information available to interpret study findings.

AiCure’s digital biomarker platform collects and analyzes visual and auditory cues through a patient’s smartphone camera, finding critical disease characteristics and behavioral trends. Through accurate data capture, the platform assists in ensuring the integrity of clinical trial data throughout the study. By widening access to these algorithms, AiCure will empower the pharmaceutical industry and scientific community to enhance their understanding of symptomology, drug dosing side effects, and stratified illness variations.

While digital biomarkers aid in eliminating the blind spots of infrequent and subjective in-person visits, their exclusivity in the scientific community is still flying blind when it comes to gauging the impact and validity of these proprietary algorithms, constraining their use and the weight they carry during regulatory conversations. Through an open science framework, they hope to unearth the potential of digital biomarkers to safeguard the success of a trial and understand a drug’s impact and equip sites to offer each patient the support they require.